Wen Chen Yeh
Chief Tech/Sci/R&D Officer bij Surrozen Operating, Inc.
Profiel
Wen Chen Yeh is currently the Chief Scientific Officer at Surrozen Operating, Inc. He previously worked at Amgen, Inc. as a Scientific Executive Director from 2006 to 2016.
He also worked as a Professor at the University of Toronto.
In addition, he was the former Chief Scientific Officer at Surrozen, Inc. from 2016 to 2023.
Mr. Yeh holds a doctorate degree from The Johns Hopkins University and National Taiwan University.
Actieve functies van Wen Chen Yeh
| Bedrijven | Functie | Begin |
|---|---|---|
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01-05-2016 |
Eerdere bekende functies van Wen Chen Yeh
| Bedrijven | Functie | Einde |
|---|---|---|
| SURROZEN, INC. | Chief Tech/Sci/R&D Officer | 31-07-2023 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01-04-2016 |
| University of Toronto | Corporate Officer/Principal | - |
Opleiding van Wen Chen Yeh
| The Johns Hopkins University | Doctorate Degree |
| National Taiwan University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
